Comparison Between Triphasic CT Abdomen and EUS-FNB in Characterization of Pancreatic Lesion

ConditionsEUS Guided Biopsy CT Scan Pancreatic Lesions Located at the Body or the Tail

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorAssiut University

About this trial

evaluate the relationship between triphasic CT and EUS findings and the characterization of pancreatic lesions.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

*Adult patients (age>18 years) presenting with focal pancreatic lesions detected on initial imaging.

Patients referred for further evaluation by triphasic CT and/or EUS-guided biopsy.

Patients able to provide informed consent

Disqualifiers

Previous pancreatic surgery.

Known metastatic disease at presentation.

Contraindications to contrast-enhanced CT (e.g. severe renal impairment, contrast allergy)

Contraindications to EUS or biopsy (e.g., coagulopathy uncorrected, severe cardiopulmonary instability).

Trial population

Adult patients (age\>18 years) presenting with focal pancreatic lesions detected on initial imaging.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Full clinical history (pain, jaundice, weight loss, pancreatitis history). Physical examination with focus on abdominal and systemic findings.
Diagnostic test
Full clinical history (pain, jaundice, weight loss, pancreatitis history). Physical examination with focus on abdominal and systemic findings.

Treatment groups

50 Participants

are divided into 2 treatment groups

Group A: Patients assessed by Triphasic CT scan1 intervention

Group B: Patients assessed by Endoscopic Ultrasound (EUS)&Tissue Sampling1 intervention

Trial outcomes

Primary outcomes

Diagnostic accuracy of triphasic CT compared to EUS-guided biopsy in differentiating benign from malignant pancreatic lesions.

the diagnostic accuracy of triphasic CT compared to EUS-guided biopsy in differentiating benign and malignant pancreatic lesions, calculated in terms of sensitivity, specificity, PPV, NPV, and overall accuracy, using final histopathological diagnosis as the reference standard.

Time frame

one year

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: